Trial Profile
A 4 Week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2013
Price :
$35
*
At a glance
- Drugs AZD 1981 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms Columbus
- Sponsors AstraZeneca
- 01 Jul 2013 Results published in Respiratory Medicine.
- 16 Nov 2011 Planned patient number is 130 as reported by European Clinical Trials Database.
- 12 Jan 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov. Actual end date reported as 1 Dec 2008.